The Food and Drug Authority released a public health warning, last March 2, 2021, on products containing hydroquinone and tretinoin. These products are found to be non-compliant with the existing standards and may cause potential harm to the consuming public.
The use of tretinoin or hydroquinone, in itself, is not a problem. However, products that contain these drugs are categorized differently according to the concentration of tretinoin or hydroquinone.
Home remedy products should only contain less than or equal to 2% hydroquinone and less than or equal to 0.025% tretinoin. These products can be sold without supervision of a pharmacist provided that its labeling to proper usage is adhered to.
Over-the-counter or OTC products can have more than 2% but less than 3% hydroquinone. Products with tretinoin, on the other hand, should only have less than or equal to 0.05% tretinoin in it. These products should only be dispensed by a licensed pharmacist.
Lastly, products that contain more than 3% hydroquinone or more than 0.05% tretinoin are considered Prescription drugs. These products should only be used and bought with a prescription from a licensed physician.
Combination of hydroquinone and tretinoin can be used as home remedies, provided that they do not exceed 2% and 0.025%, respectively.
Brilliant Skin Essential Rejuvenating Toner and Facial Cream and Aryana Beauty and Body Doctor Skin Night Cream could have tretinoin and hydroquinone concentrations that either require a pharmacist’s supervision or a physician’s prescription.
Improper usage of tretinoin can lead to skin redness, dryness, burning, scaling, and sometimes worsening of acne. While hydroquinone, on the other hand, can can also cause skin irritation, redness, dryness, and darkening.
If you would like to check if the product you are going to buy or going to use is notified by fda, you may visit https//verification.fda.gov.ph.
To report any sale, distribution, complaint/adverse event on use of violation cosmetic product, you may accessed email@example.com
Source” FDA Administrative order 13 series 1999